As 2024 draws to a close, we’re celebrating a wonderful year of content.
From insightful expert Q&As and peer-reviewed articles to conference highlights and a wealth of medical education, it’s been a year filled with content that we hope has been useful to our audience. We’ve had the privilege of connecting with leading experts and working alongside medical societies to support the medical community with high-quality, easily accessible content.
Here are just a few of our standout moments from the past year.
Most read article:
Camlipixant: A New Treatment Option for Refractory Chronic Cough?
Prof. Stephen K Field reviews camlipixant, a potential new treatment option for patients with refractory chronic cough.
Most watched video:
Driving collaboration to address future challenges in ophthalmology
In this interview, Dr SriniVas Sadda, President of ARVO (2024-2025), discusses the pressing challenges and emerging opportunities in treating retinal diseases.
Most listened to podcast:
JAK inhibitors: A new player for hard-to-treat skin conditionsDr Bill Damsky joins us to discuss the impact JAK inhibitors have on tackling a wide range of skin conditions. We explore their journey from proof-of-concept to becoming a treatment option for traditionally hard-to-treat and rare conditions, touch on the ongoing safety debate, and highlight their future impact.
Most viewed news story:
SOUL results indicate oral semaglutide reduces MACE risk by 14% in adults with T2D
This articles reports on the top-line results from the SOUL trial, showing that oral semaglutide significantly reduces the risk of major adverse cardiovascular events in adults with T2D who have established atherosclerotic cardiovascular disease and/or chronic kidney disease.
Don’t miss out on our latest content and initiatives in 2025—follow us on LinkedIn and stay connected.
